Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Hemangiosarcoma

• A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
• Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
• Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
• A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
• Cemiplimab for Secondary Angiosarcomas
• Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma
• AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
• Propranolol in Angiosarcoma
• Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
• Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
• Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
• A Study of Oraxol in Subjects With Cutaneous Angiosarcoma
• Paclitaxel-Avelumab for Angiosarcoma
• Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
• A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
• Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
• Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma
• Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequentia
• Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.
• Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
• Evaluation of Votrient in Angiosarcoma
• Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
• Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
• Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
• Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
• A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
• Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
• Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
• Sorafenib in Treating Patients With Angiosarcoma That is Locally Advanced, Metastatic, or Unable to Be Removed by Surgery
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma
• Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
• Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
• Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma